SCHEMBL3974547

SCHEMBL3974547

CNC(=O)c1ccc(C)nc1Nc1cc(C(C)(C)C)nn1-c1cccc(F)c1OC

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK14 Q16539 8/20 0.39
MAPK12 P53778 5/20 0.39
MAPK11 Q15759 5/20 0.39
MAPK13 O15264 4/20 0.39
RIPK1 Q13546 2/20 0.38
NTRK1 P04629 4/20 0.38
BRAF P15056 3/20 0.37
RAF1 P04049 2/20 0.37
PTK2B Q14289 2/20 0.37
ADORA2A P29274 1/20 0.36
JAK1 P23458 4/20 0.36
TYK2 P29597 3/20 0.36
KCNH2 Q12809 1/20 0.36
NTRK3 Q16288 3/20 0.35
NTRK2 Q16620 3/20 0.35
PLK4 O00444 1/20 0.35
ACOX3 O15254 1/20 0.35
MAP3K7 O43318 1/20 0.35
DYRK3 O43781 1/20 0.35
JAK2 O60674 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3975140 0.91 MAPK14 (0.41) MAPK14MAPK12MAPK11MAPK13NTRK1
SCHEMBL3982040 0.87 RIPK1 (0.45) MAPK14MAPK12MAPK11MAPK13RIPK1
SCHEMBL3977193 0.80 MAPK14 (0.43) MAPK14MAPK12MAPK11MAPK13NTRK1
SCHEMBL3972865 0.77 MAPK14 (0.42) MAPK14MAPK12MAPK11MAPK13BRAF
SCHEMBL3975282 0.74 MAPK14 (0.42) MAPK14MAPK12MAPK11MAPK13MAPK9
SCHEMBL3974011 0.74 MAPK14 (0.42) MAPK14MAPK12MAPK11MAPK13NTRK1
SCHEMBL3980494 0.74 MAPK14 (0.59) MAPK14MAPK12MAPK11MAPK13NTRK1
SCHEMBL3973588 0.74 MAPK14 (0.56) MAPK14MAPK12MAPK11MAPK13NTRK1
SCHEMBL3980491 0.73 RIPK1 (0.45) MAPK14MAPK12MAPK11MAPK13RIPK1
SCHEMBL3973341 0.73 MAPK14 (0.40) MAPK14MAPK12MAPK11MAPK13BRAF

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090209451-A1 HETEROARYLAMINOPYRAZOLE DERIVATIVES USEFUL FOR THE TREATMENT OF DIABETES BAYER PHARMACEUTICALS CORPORATION (US) 2009-08-20 US disclosed
US-20090209451-A1 HETEROARYLAMINOPYRAZOLE DERIVATIVES USEFUL FOR THE TREATMENT OF DIABETES BAYER PHARMACEUTICALS CORPORATION (US) 2009-08-20 US disclosed
US-20090209451-A1 HETEROARYLAMINOPYRAZOLE DERIVATIVES USEFUL FOR THE TREATMENT OF DIABETES BAYER PHARMACEUTICALS CORPORATION (US) 2009-08-20 US disclosed
US-7517878-B2 Heteroarylaminopyrazole derivatives useful for the treatment of diabetes BAYER PHARAMCEUTICALS CORPORATION (US) 2009-04-14 US disclosed
US-7517878-B2 Heteroarylaminopyrazole derivatives useful for the treatment of diabetes BAYER PHARAMCEUTICALS CORPORATION (US) 2009-04-14 US disclosed
US-7517878-B2 Heteroarylaminopyrazole derivatives useful for the treatment of diabetes BAYER PHARAMCEUTICALS CORPORATION (US) 2009-04-14 US disclosed
US-20050192294-A1 Heteroarylaminopyrazole derivatives useful for the treatment of diabetes BAYER PHARMACEUTICALS CORPORATION (US) 2005-09-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050192294-A1 Heteroarylaminopyrazole derivatives useful for the treatment of diabetes GPR119, GOT2, IAPP MAPK14 2768/4885MAPK12 2241/4885MAPK11 2727/4885
US-20090209451-A1 HETEROARYLAMINOPYRAZOLE DERIVATIVES USEFUL FOR THE TREATMENT OF DIABETES GPR119, GOT2, IAPP MAPK14 2768/4885MAPK12 2241/4885MAPK11 2727/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.